Literature DB >> 27283035

Analysis of FOXL2 detects three novel mutations and an atypical phenotype of blepharophimosis-ptosis-epicanthus inversus syndrome.

Anna Krepelova1, Martina Simandlova1, Marketa Vlckova1, Pavel Kuthan2, Andrea L Vincent3,4, Petra Liskova2,5.   

Abstract

BACKGROUND: Mutations in FOXL2 are known to cause autosomal dominant blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), variably associated with premature ovarian failure. In this study, we report results of mutational screening in a Czech and Slovak patient population with BPES.
DESIGN: Case series. PARTICIPANTS: Thirteen probands of Czech and one proband of Slovak origin with BPES and their available family members.
METHODS: Sanger sequencing and multiplex ligation-dependent probe amplification in 14 probands with BPES. Targeted mutational screening in first-degree relatives. MAIN OUTCOME MEASURES: Genetic characterization and phenotype evaluation in Czech and Slovak individuals with BPES and their family members.
RESULTS: Eight different mutations were detected including three novel ones: c.5T>G; p.(Met2Arg), c.197C>A; p.(Ala66Glu) and c.701_702insTGCAGCCGCAGCGGCTGCAGCAGCTGCGGCTGCAGCCGC; p.(Ala222_Ala234dup). In one family, the molecular genetic cause of disease was not identified by the methodology used. In 13 pedigrees, a negative family history suggested a de novo origin, which could be confirmed by targeted mutational screening in four families. One 62-year-old female with the c.663_692dup30 mutation had an atypical phenotype presenting as moderate ptosis compensated by frontalis muscle contraction, no epicanthus inversus and no premature ovarian failure.
CONCLUSIONS: The de novo mutation rate in FOXL2 is exceptionally high compared with other dominant disorders manifesting with an ocular phenotype. In cases reporting a negative family history, careful examination of both parents is important to exclude mild features of the BPES phenotype.
© 2016 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  FOXL2; blepharophimosis-ptosis-epicanthus inversus syndrome; phenotype

Mesh:

Substances:

Year:  2016        PMID: 27283035     DOI: 10.1111/ceo.12783

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

1.  Ovarian Reserve and ART Outcomes in Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome Patients With FOXL2 Mutations.

Authors:  Tingting Meng; Wenzhe Zhang; Rongrong Zhang; Jie Li; Yuan Gao; Yingying Qin; Xue Jiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

2.  New STAT3-FOXL2 pathway and its function in cancer cells.

Authors:  Yangyang Han; Jun Wu; Weiwei Yang; Di Wang; Tianliang Zhang; Min Cheng
Journal:  BMC Mol Cell Biol       Date:  2019-06-20

Review 3.  The Genetic and Clinical Features of FOXL2-Related Blepharophimosis, Ptosis and Epicanthus Inversus Syndrome.

Authors:  Cécile Méjécase; Chandni Nigam; Mariya Moosajee; John C Bladen
Journal:  Genes (Basel)       Date:  2021-03-04       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.